[go: up one dir, main page]

PT1066060E - Celulas estaminais mesenquimais como imunossupressores - Google Patents

Celulas estaminais mesenquimais como imunossupressores

Info

Publication number
PT1066060E
PT1066060E PT99911322T PT99911322T PT1066060E PT 1066060 E PT1066060 E PT 1066060E PT 99911322 T PT99911322 T PT 99911322T PT 99911322 T PT99911322 T PT 99911322T PT 1066060 E PT1066060 E PT 1066060E
Authority
PT
Portugal
Prior art keywords
cells
mesenchineal
immunosupressors
stamina
stem cells
Prior art date
Application number
PT99911322T
Other languages
English (en)
Inventor
Joseph D Mosca
Kevin R Mcintosh
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of PT1066060E publication Critical patent/PT1066060E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99911322T 1998-04-03 1999-03-12 Celulas estaminais mesenquimais como imunossupressores PT1066060E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8067898P 1998-04-03 1998-04-03

Publications (1)

Publication Number Publication Date
PT1066060E true PT1066060E (pt) 2003-12-31

Family

ID=22158925

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99911322T PT1066060E (pt) 1998-04-03 1999-03-12 Celulas estaminais mesenquimais como imunossupressores

Country Status (11)

Country Link
US (1) US6797269B2 (pt)
EP (1) EP1066060B1 (pt)
JP (1) JP2002510655A (pt)
AT (1) ATE246938T1 (pt)
AU (1) AU2999199A (pt)
CA (1) CA2326838C (pt)
DE (1) DE69910362T2 (pt)
DK (1) DK1066060T3 (pt)
ES (1) ES2205792T3 (pt)
PT (1) PT1066060E (pt)
WO (1) WO1999051275A2 (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1062321E (pt) * 1998-03-13 2005-05-31 Osiris Therapeutics Inc Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SK287940B6 (sk) * 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP1349918B1 (en) 2000-12-06 2014-08-06 Anthrogenesis Corporation Method of collecting placental stem cells
CA2856986C (en) * 2001-02-14 2019-08-13 Anthrogenesis Corporation Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders
ES2558626T3 (es) 2001-02-14 2016-02-05 Anthrogenesis Corporation Placenta post-parto de mamíferos, su uso y células madre placentarias de la misma
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298862B1 (en) * 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
AU2012205269B2 (en) * 2004-03-22 2015-08-27 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
ES2708627T3 (es) * 2004-03-22 2019-04-10 Mesoblast Int Sarl Células madre mesenquimales y sus usos
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
EP2471907B1 (en) 2005-12-29 2018-09-26 Celularity, Inc. Placental stem cell populations
EP1971679B1 (en) 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
CA3124132A1 (en) 2006-01-23 2007-08-02 Abt Holding Company Mapc therapeutics without adjunctive immunosuppressive treatment
DK2772535T3 (da) 2006-05-31 2022-07-04 Childrens Medical Center ABC5-positive mesenkymale stamceller som immunmodulatorer
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
ES2441560T3 (es) 2006-11-03 2014-02-05 Aastrom Biosciences, Inc. Poblaciones celulares mixtas para la reparación de tejidos y técnica de separación para el procesamiento celular
KR20150039214A (ko) 2007-02-12 2015-04-09 안트로제네시스 코포레이션 태반 줄기세포를 이용한 염증 질환의 치료
US20100291042A1 (en) 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
DE102007028687A1 (de) * 2007-06-21 2008-12-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Therapeutische Zusammensetzung zur Behandlung einer Autoimmunerkrankung, umfassend eine autologe Antigenzusammensetzung, sowie Verfahren und Vorrichtungen zur autologen Antikörper- und Antigenproduktion
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
KR101955140B1 (ko) 2007-09-28 2019-03-06 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
WO2009050282A1 (en) * 2007-10-17 2009-04-23 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
WO2009134429A2 (en) * 2008-05-02 2009-11-05 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
RU2376985C1 (ru) * 2008-07-17 2009-12-27 Владислав Николаевич Ласкавый Средство для активации стволовых клеток
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
NZ591294A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Treatment of stroke using isolated placental cells
CA2965883C (en) 2008-08-22 2020-05-12 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
RU2562154C2 (ru) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
US10098333B2 (en) * 2008-12-09 2018-10-16 University Of Southern California Method for treating an SLE-like autoimmune disease in a human subject consisting of administering stem cells from human exfoliated deciduous teeth (SHED) and erythropoietin (EPO) to said human subject
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
CN102625829B (zh) * 2009-07-21 2015-05-06 Abt控股公司 干细胞用于减少白细胞外渗的用途
KR101718773B1 (ko) * 2009-12-08 2017-03-22 더 보드 오브 트러스티스 오브 더 유니버시티 오브 일리노이 줄기 세포를 이용한 면역 조정 방법 및 장치
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
KR20240096688A (ko) 2010-04-07 2024-06-26 셀룰래리티 인코포레이티드 태반 줄기 세포를 사용한 혈관신생
US8562973B2 (en) 2010-04-08 2013-10-22 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
CA2798895A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
CA2804750C (en) 2010-07-13 2022-05-10 Anthrogenesis Corporation Methods of generating natural killer cells
EP2625263B1 (en) 2010-10-08 2020-03-11 Terumo BCT, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CA2837871C (en) 2011-06-01 2021-12-07 Anthrogenesis Corporation Treatment of pain using placental stem cells
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN113138279A (zh) 2012-06-27 2021-07-20 法姆制药有限责任公司 融合蛋白组合物的应用
HK1218515A1 (zh) 2013-02-05 2017-02-24 人类起源公司 来自胎盘的自然杀伤细胞
EP2964238B1 (en) 2013-02-19 2021-01-13 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
ES2827250T3 (es) 2013-04-12 2021-05-20 Houston Methodist Hospital Mejora de órganos para trasplante
CN105517587B (zh) 2013-05-10 2019-02-19 儿童医学中心公司 伤口愈合与组织工程
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015023147A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
PT3091991T (pt) * 2013-12-13 2020-02-04 Swedish Stromabio Ab Composições imunomodulatórias
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
KR20150136389A (ko) * 2014-05-27 2015-12-07 삼성전자주식회사 관절염 예방 또는 치료용 조성물, 키트, 및 이를 이용한 관절염 예방 또는 치료 방법
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CA3013457A1 (en) 2016-02-04 2017-08-10 Longeveron Llc Mesenchymal stem cells as vaccine adjuvants and methods for using the same
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
MX2020011297A (es) 2018-04-25 2020-11-18 Childrens Medical Center Ligandos y substratos de abcb5.
KR20230004669A (ko) * 2020-04-20 2023-01-06 롱에버론 인코포레이티드 효력 검정
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
CN114480413B (zh) * 2022-01-14 2022-11-04 北京贝来生物科技有限公司 一种活化肿瘤免疫应答的基因修饰干细胞制备方法
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024267A1 (en) * 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5747299A (en) * 1994-06-23 1998-05-05 The Board Of Trustees Of The Leland Stanford Junior University Anergy genes

Also Published As

Publication number Publication date
CA2326838A1 (en) 1999-10-14
DE69910362T2 (de) 2004-06-24
DE69910362D1 (de) 2003-09-18
JP2002510655A (ja) 2002-04-09
ES2205792T3 (es) 2004-05-01
EP1066060A2 (en) 2001-01-10
AU2999199A (en) 1999-10-25
EP1066060B1 (en) 2003-08-13
DK1066060T3 (da) 2003-11-24
WO1999051275A2 (en) 1999-10-14
US6797269B2 (en) 2004-09-28
WO1999051275A3 (en) 1999-12-09
CA2326838C (en) 2008-12-23
US20020044923A1 (en) 2002-04-18
ATE246938T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
PT1066060E (pt) Celulas estaminais mesenquimais como imunossupressores
EP1553975A4 (en) OPTIMIZED FC VARIANTS AND MANUFACTURING METHOD THEREFOR
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
NO331101B1 (no) In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet.
AR026994A1 (es) Nuevas construcciones de expresion en plantas.
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
BR9612258B1 (pt) inibidores de enzima conversora de interleucina-1beta, bem como composição farmacêutica.
ES2191702T3 (es) Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
DE69516847D1 (de) Chlorpyrimidine als zwischenprodukte
TR200401348T4 (tr) Yapay elyaf halatların kontrol edilmesi için elektrik kontağı
MXPA06010419A (es) Metodos para modular las respuestas inmunes al modular la funcion tim-1, tim-2 y tim-4.
DE60037007D1 (de) Angereicherte zentralnervensystem-zellpopulationen
AU2001258373A1 (en) Method for identifying helicobacter antigens
IS7154A (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
DK1007666T3 (da) Neurturinreceptor
ATE391727T1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
HUP0004258A2 (hu) Eljárás a termés fokozására növényekben
EA200702092A1 (ru) Липосомная композиция для индукции иммунитета
AR017574A1 (es) Gen que codifica la tanatina, vector que lo contiene y plantas transformadas obtenidas, resistentes a las enfermedades
GB2412991A (en) Interactive real time grid-based graphical trading system
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
DE60225530D1 (de) Phosphorylierte glyoxalase i und deren verwendung